Welcome to our dedicated page for Moleculin Biotec news (Ticker: MBRX), a resource for investors and traders seeking the latest updates and insights on Moleculin Biotec stock.
Moleculin Biotech, Inc. (NASDAQ: MBRX) is a clinical stage pharmaceutical company focused on developing therapies for hard-to-treat tumors and viruses. Known for its innovative drug candidates, Moleculin's pipeline aims to address significant unmet medical needs. The company's flagship product, Annamycin, is a next-generation anthracycline designed to overcome multidrug resistance mechanisms and minimize cardiotoxicity. Annamycin is currently in Phase II clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.
Moleculin's research is rooted in discoveries from the acclaimed M.D. Anderson Cancer Center. In addition to Annamycin, the company is developing WP1066, an Immune/Transcription Modulator targeting brain tumors, pancreatic cancer, and other malignancies. WP1066 aims to inhibit oncogenic transcription factors such as p-STAT3 while stimulating the patient's immune response.
Another promising candidate, WP1220, an analog of WP1066, is being developed for the topical treatment of cutaneous T-cell lymphoma. The company also has a robust antimetabolite portfolio, including WP1122, which is being investigated for its potential in treating both viral infections and various cancers.
Recent achievements highlight Moleculin's significant progress. Positive preclinical data for Annamycin were presented at the American Association for Cancer Research (AACR) Annual Meeting, demonstrating its non-cardiotoxic properties and potent inhibition of topoisomerase II-beta. Annamycin has also received Orphan Drug Designation from both the FDA and the European Medicines Agency (EMA) for AML, providing Moleculin with extended market exclusivity and reduced regulatory fees.
Financially, Moleculin maintains a solid footing with sufficient capital to support its ongoing clinical trials and future projects. The company's recent financial report indicates a strategic focus on advancing its clinical and regulatory strategies. With multiple patents issued and pending, Moleculin continues to strengthen its intellectual property portfolio, positioning itself favorably for potential partnerships and market expansion.
Collaborations with leading institutions such as Northwestern University and funding from entities like the National Institutes of Health (NIH) underscore the robust support for Moleculin's initiatives. The company's innovative approach and commitment to addressing challenging medical conditions make it a noteworthy entity in the biopharmaceutical landscape.
For more details, please visit Moleculin's website and connect on Twitter, LinkedIn, and Facebook.
Moleculin Biotech reported its Q3 2024 financial results and provided a corporate update. Key highlights include the initiation of dosing in the Phase 3 MIRACLE trial for Annamycin in Q1 2025. The median durability of CRc in the MB-106 trial has exceeded 8 months. Moleculin hosted a virtual AML KOL event and appointed Dr. Daniel D. Von Hoff to its Scientific Advisory Board.
Financially, R&D expenses rose to $4.9 million from $3.3 million year-over-year, while G&A expenses decreased to $2.2 million from $2.6 million. The company closed a $5.5 million financing and has $9.4 million in cash reserves, expected to fund operations into Q1 2025.
Upcoming milestones include the first subject treated in the MIRACLE trial in Q1 2025 and final data readout for the STS lung metastases trial in 2025. Moleculin will host a conference call on November 11, 2024, at 8:30 AM ET to discuss these updates.
Moleculin Biotech (MBRX) has scheduled its third quarter 2024 financial results announcement for November 8, 2024. The company will host a conference call and webcast to discuss operational and financial results on November 11, 2024, at 8:30 AM ET. Participants can join via phone using the numbers (877) 407-0832 (domestic) or (201) 689-8433 (international). The webcast will be available on the company's website and archived for 90 days.
Moleculin Biotech (NASDAQ: MBRX) has appointed Dr. Daniel D. Von Hoff to its Annamycin Scientific Advisory Board. Dr. Von Hoff, a Distinguished Professor at the Translational Genomics Research Institute and expert in pancreatic cancer, joins following promising preclinical evidence of Annamycin's potential in treating pancreatic cancer presented at AACR. Annamycin is currently in clinical trials for treating relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma lung metastases. The drug holds Fast Track Status and Orphan Drug Designation from FDA for AML treatment, plus Orphan Drug Designation for soft tissue sarcoma and from EMA for AML.
Moleculin Biotech, Inc. (Nasdaq: MBRX) has announced that the transcript from its recent Virtual Acute Myeloid Leukemia (AML) Key Opinion Leader (KOL) event is now available. The event featured Moleculin's executives and renowned AML experts discussing the potential of Annamycin in changing the AML treatment landscape. The transcript can be accessed on the company's website and SEC Filings page.
The event included an overview of Annamycin, the use of anthracyclines, and Moleculin's recently announced global Phase 3 pivotal trial (MIRACLE) for treating AML patients who are refractory to or relapsed after induction therapy. Walter Klemp, CEO of Moleculin, expressed gratitude to the KOLs for their insights and support, highlighting the growing body of positive preliminary data for Annamycin in addressing the unmet need for safe and effective therapies for R/R AML.
Moleculin Biotech, Inc. (Nasdaq: MBRX) has announced a Virtual Acute Myeloid Leukemia (AML) KOL event scheduled for October 14, 2024, from 11:00 AM to 1:00 PM ET. The event will feature discussions on Annamycin, the company's drug candidate for treating relapsed or refractory AML, and its ongoing pivotal Phase 3 clinical trial (the 'MIRACLE' trial).
Key participants include Moleculin's management team and renowned AML experts from prestigious institutions. The event will cover topics such as the use of anthracyclines, Annamycin's potential impact on AML treatment, and details about the global Phase 3 trial. Interested parties can join via conference call or watch the live video webcast on Moleculin's website.
Moleculin Biotech, Inc. (Nasdaq: MBRX), a late-stage pharmaceutical company focusing on hard-to-treat tumors and viruses, has announced its participation in two upcoming investor conferences. The first is the 3rd Annual ROTH Healthcare Opportunities Conference on October 9, 2024, where Moleculin will participate in a panel discussion on Innovative Therapies for Liquid Tumors at 1:15 PM ET. The panel will cover drug developments, competitive positioning, and upcoming data readouts.
The second event is the 2024 Healthcare Virtual Summit, presented by Maxim Group and hosted by M-Vest, scheduled for October 16, 2024, at 3:00 PM ET. Moleculin will participate in a fireside chat format. This virtual event will be accessible to M-Vest members, with registration available online. Both conferences offer opportunities for Moleculin to showcase its drug candidates and engage with the investor community.
Moleculin Biotech (Nasdaq: MBRX) presented positive in vivo efficacy data of Annamycin in orthotopic and experimental lung metastatic models of sarcoma at the IASLC 2024 World Conference on Lung Cancer. Key findings include:
1. Annamycin demonstrated high uptake and retention in lung parenchyma of mice and rats, exceeding doxorubicin levels by 10- to 30-fold.
2. Treatment with Annamycin resulted in statistically significant inhibition of tumor growth and extension of survival in orthotopic lung cancer models.
3. Annamycin exhibited consistent efficacy in vivo in orthotopic and experimental lung metastatic models of sarcoma, breast, and colon cancer.
4. Preclinical tests and ongoing clinical studies show Annamycin has a better cardiac safety profile compared to doxorubicin, with no cardiotoxicity observed.
Annamycin is currently in clinical trials for relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases, with Fast Track Status and Orphan Drug Designations from FDA and EMA.
Moleculin Biotech, Inc. (Nasdaq: MBRX) has announced that CEO Walter Klemp participated in a Virtual Investor 'What this Means' segment. The segment focused on the company's Phase 2 clinical trial of WP1066, a STAT3 inhibitor, in combination with radiation therapy for the treatment of glioblastoma in adults. This investigator-initiated study (NU 21C06) is being conducted under Northwestern University's IND, which references Moleculin's FDA-cleared IND from April 2022.
The trial is funded by the National Institutes of Health (NIH) and BrainUp®, a non-profit organization dedicated to brain cancer awareness. Moleculin, a Phase 3 clinical-stage pharmaceutical company, is developing a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses. The Virtual Investor segment featuring Moleculin is now available for viewing online.
Moleculin Biotech (Nasdaq: MBRX) has announced the start of an investigator-initiated Phase 2 clinical trial evaluating WP1066 in combination with radiation therapy for the treatment of glioblastoma. The study, conducted at Northwestern University, is funded by the NIH and BrainUp®. WP1066 is Moleculin's Immune/Transcription Modulator designed to stimulate immune response to tumors by inhibiting regulatory T cells and oncogenic transcription factors.
The trial aims to address the unmet need in glioblastoma treatment, with four subjects already active and expectations to fill the safety lead-in group of six subjects soon. Glioblastoma is an aggressive brain tumor with a median survival of only 15 months. Moleculin has received Orphan Drug Designation for WP1066 for brain tumors and Rare Pediatric Disease designation for three other pediatric indications.
Moleculin Biotech (MBRX), a Phase 3 clinical stage pharmaceutical company, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event will take place from September 9-11, 2024 in New York, NY.
Key points:
- Walter Klemp, Chairman and CEO, will present at the conference
- Management will be available for in-person one-on-one meetings with qualified investors
- A video webcast of the presentation will be accessible on-demand from September 9, 2024, at 7:00 AM ET
- The webcast will be available on the Events page in the Investors section of Moleculin's website
- The webcast replay will be archived for 90 days following the event
FAQ
What is the current stock price of Moleculin Biotec (MBRX)?
What is the market cap of Moleculin Biotec (MBRX)?
What is Moleculin Biotech's lead product candidate?
What are the key focus areas of Moleculin Biotech's research?
What recent achievements has Moleculin Biotech reported?
How is Moleculin Biotech financially positioned?
What collaborations is Moleculin Biotech involved in?
What is the significance of Annamycin's Orphan Drug Designation?
What is WP1066, and what does it target?
What is WP1220 used for?
What is the potential of WP1122?
Where can I find more information about Moleculin Biotech?
